Clear cell carcinoma of the ovary: A review of the literature
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712 · cited 1×
“ARID1A, a tumor suppressor, appears to be mutated in close to 50% of CCC cases [37,43,44,49].”
BackgroundOvarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050232 · Cited by 814 · cited 1×
“CCC tumors have low levels of chromosomal instability and low proliferation rates, with high frequency of phosphoinositide 3-kinase catalytic alpha (PIK3CA mutations) [10,22,26,29].”
BackgroundPPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints
Lu, X., Nannenga, B., & Donehower, L. A. (2005) · Genes & Development · doi:10.1101/gad.1291305 · Cited by 389
Kobayashi, H., Sumimoto, K., Moniwa, N., Imai, M., Takakura, K., Kuromaki, T., Morioka, E., Arisawa, K., & Terao, T. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00754.x · Cited by 305 · cited 1×
“In a large population-based study from Japan, endometriosis resulted in a nine-fold increased risk of developing ovarian cancer [73].”
BackgroundLeu, J. I., Crissey, M. A. S., Leu, J. P., Ciliberto, G., & Taub, R. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.2.414-424.2001 · Cited by 134 · cited 1×
“Pathways appear to involve interleukin (IL)- and signal transducer and activator of transcription 3 (STAT3) converging on HNF1B, HIF1A, and endothelial PAS domain-containing protein 1 is (EPAS1) [43–46].”
Background
Cited by
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Ovary
Okamoto, A., Glasspool, R. M., Mabuchi, S., Matsumura, N., Nomura, H., Itamochi, H., Takano, M., Takano, T., Susumu, N., Aoki, D., et al. (2014) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000289 · Cited by 164
“In North America and Europe, CCC is the thirdmost common histologic subtype of epithelial ovarian cancer, with an estimated prevalence of 1% to 12%.(2) Recent Surveillance, Epidemiology, and EndResults data revealed that the incidences of CCC inwomen living inUnited Stateswere 4.”
BackgroundExpression and Significance of CD44, CD47 and c-met in Ovarian Clear Cell Carcinoma
Wang, H., Tan, M., Zhang, S., Li, X., Gao, J., Zhang, D., Hao, Y., Gao, S., Liu, J., & Lin, B. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16023391 · Cited by 83
“Compared with other ovarian epithelial cancer subtypes, OCCC presents with characteristic histological and biological changes, such as early staging, higher malignancy, susceptibility to drug resistance, higher risk of relapse and worse prognosis [1,2].”
BackgroundChao, A., Lai, C.-H., Wang, T.-H., Jung, S.-M., Lee, Y.-S., Chang, W.-Y., Yang, L.-Y., Ku, F.-C., Huang, H.-J., Chao, A.-S., et al. (2018) · Journal of Molecular Medicine · doi:10.1007/s00109-018-1643-8 · Cited by 20
Metadata
- Authors
- del Carmen, M. G., Birrer, M., & Schorge, J. O.
- Venue
- Gynecologic Oncology
- Publisher
- Elsevier BV
- Published
- 2012-09
- Volume
- 126
- Issue
- 3
- Pages
- 481-490
- ISSN
- 0090-8258 (ISSN-L)
- OpenAlex
- W1970221409
- Cited by
- 246
- References
- 6
- FWCI
- 20.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.